B-Cell Maturation Antigen (BCMA)

Overview

B-Cell Maturation Antigen (BCMA) is a protein that may be found on the surface of myeloma cells. BCMA may be used as a target to help treatments find and destroy myeloma cells.

Explore Tags

Myeloma Treatments

The following is a listing of myeloma treatments associated with this tag.

All Treatments

View all treatments in development for myeloma patients around the US.

Verified ABBV-383
ABBV-383

ABBV-383 is a bi-specific antibody, meaning that it interacts with two molecules in your body. One molecule is called B-Cell Maturation Antigen (BMCA) and is found on your multiple myeloma cells. The second is called CD3 and is present on your killer T-cells.

Verified Belantamab Mafodotin
Belantamab Mafodotin Blenrep®

Belantamab Mafodotin (formerly GSK2857916) is an antibody-drug conjugate (ADC) directed against the B-cell maturation antigen (BCMA).

Verified SEA-BCMA
SEA-BCMA

SEA-BCMA is a monoclonal antibody that targets the B-Cell Maturation Antigen (BCMA) and is made with Sugar Engineered Antibody (SEA) technology. Researchers believe this approach may improve immune response to cancer cells.

SparkCures Verified Accurate, up-to-date information. Learn more


Untreated / Newly Diagnosed Multiple Myeloma

The following is a listing of treatments in development for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.

Early Relapse Multiple Myeloma

The following is a listing of treatments in development for patients with multiple myeloma who have received one to two prior lines of therapy.

Verified ABBV-383
ABBV-383

ABBV-383 is a bi-specific antibody, meaning that it interacts with two molecules in your body. One molecule is called B-Cell Maturation Antigen (BMCA) and is found on your multiple myeloma cells. The second is called CD3 and is present on your killer T-cells.

Verified Belantamab Mafodotin
Belantamab Mafodotin Blenrep®

Belantamab Mafodotin (formerly GSK2857916) is an antibody-drug conjugate (ADC) directed against the B-cell maturation antigen (BCMA).

SparkCures Verified Accurate, up-to-date information. Learn more


Late Relapse Multiple Myeloma

The following is a listing of treatments in development for patients with multiple myeloma who have received three or more prior lines of therapy.

Verified ABBV-383
ABBV-383

ABBV-383 is a bi-specific antibody, meaning that it interacts with two molecules in your body. One molecule is called B-Cell Maturation Antigen (BMCA) and is found on your multiple myeloma cells. The second is called CD3 and is present on your killer T-cells.

Verified Belantamab Mafodotin
Belantamab Mafodotin Blenrep®

Belantamab Mafodotin (formerly GSK2857916) is an antibody-drug conjugate (ADC) directed against the B-cell maturation antigen (BCMA).

Verified SEA-BCMA
SEA-BCMA

SEA-BCMA is a monoclonal antibody that targets the B-Cell Maturation Antigen (BCMA) and is made with Sugar Engineered Antibody (SEA) technology. Researchers believe this approach may improve immune response to cancer cells.

SparkCures Verified Accurate, up-to-date information. Learn more


Myeloma Clinical Trials

The following is a listing of myeloma clinical trials associated with this tag.

All Clinical Trials

View all active clinical trials around the US.

SparkCures Verified Accurate, up-to-date information. Learn more


Untreated / Newly Diagnosed Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

SparkCures Verified Accurate, up-to-date information. Learn more


Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

SparkCures Verified Accurate, up-to-date information. Learn more


Monoclonal Gammopathy of Undetermined Significance (MGUS)

The following is a listing of clinical trials for patients with Monoclonal Gammopathy of Undetermined Significance (MGUS).

Myeloma Tags

The following is a listing of myeloma tags that are associated with this tag.

Antibody Drug Conjugate (ADC)

Antibody Drug Conjugates (ADC) work by combining a chemotherapy drug with a monoclonal antibody. This allows the chemotherapy drug to target a specific cancer cell while limiting the damage to healthy cells.

Bispecific Antibody

A bispecific antibody is a drug that has been designed to simultaneously target two different proteins. Both targets may be expressed by a cancer cell, or these drugs may target both cancer cells and T cells.

CAR T Cell

CAR T Cell therapy is a new way to treat multiple myeloma using your own immune system to target and destroy cancer cells.

Monoclonal Antibody

Monoclonal antibodies are large, y-shaped, man-made proteins. They are able to target cancer cells by finding and attaching to unique proteins found on the cell's surface.

Resources